Cover Image
市場調查報告書

白細胞介素1 (IL1):開發中產品分析

Interleukin 1 (IL1) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 516031
出版日期 內容資訊 英文 99 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素1 (IL1):開發中產品分析 Interleukin 1 (IL1) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 99 Pages
簡介

本報告提供以白細胞介素1 (IL1)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供包含最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素1 (IL1);概要

白細胞介素 1 (IL1);治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關的開發中產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Anacor Pharmaceuticals Inc
  • Apexigen Inc
  • Cell Medica Ltd
  • Exicure Inc
  • Immune Response BioPharma Inc
  • Novartis AG
  • Omnitura Therapeutics Inc
  • Opsona Therapeutics Ltd
  • Optimum Therapeutics LLC
  • Orphit SAS
  • Peptinov SAS
  • R Pharm
  • Regeneron Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • TWi Biotechnology Inc
  • XBiotech Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC0818TDB

Summary

Interleukin 1 (IL1) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 9, 2, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Metabolic Disorders, Cardiovascular, Oncology, Central Nervous System, Genetic Disorders, Ear Nose Throat Disorders, Gastrointestinal and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Acne Vulgaris, Epidermolysis Bullosa, Inflammation, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Type 2 Diabetes, Alzheimer's Disease, Autoimmune Disorders, Bladder Cancer, Cardiovascular Risk Factors, Colorectal Cancer, Dermatological Disorders, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Osteoarthritis, Ovarian Cancer, Pain, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Sarcoidosis, Skin Inflammation, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).

Furthermore, this report also reviewsalso reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
  • The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 1 (IL1) - Overview
    • Interleukin 1 (IL1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Interleukin 1 (IL1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Anacor Pharmaceuticals Inc
    • Apexigen Inc
    • Cell Medica Ltd
    • Exicure Inc
    • Immune Response BioPharma Inc
    • Novartis AG
    • Omnitura Therapeutics Inc
    • Opsona Therapeutics Ltd
    • Optimum Therapeutics LLC
    • Orphit SAS
    • Peptinov SAS
    • R Pharm
    • Regeneron Pharmaceuticals Inc
    • Swedish Orphan Biovitrum AB
    • TWi Biotechnology Inc
    • XBiotech Inc
  • Interleukin 1 (IL1) - Drug Profiles
    • ABT-981 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AC-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-4161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-18C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diacerein CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DLX-2681 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MABp-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMN-54 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PPV-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-18C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rilonacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPH-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOBI-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • suramin hexasodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-218C3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Xilonix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ymalzen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 1 (IL1) - Dormant Products
  • Interleukin 1 (IL1) - Discontinued Products
  • Interleukin 1 (IL1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
      • May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer
      • Apr 20, 2017: XBiotech Announces Outcome of EMA's Oral Explanation Meeting
      • Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex
      • Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application
      • Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study
      • Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
      • Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology
      • Dec 16, 2016: Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
      • Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer
      • Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection
      • Oct 01, 2016: Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data in Patients with Epidermolysis Bullosa Simplex
      • Sep 23, 2016: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
      • Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU
      • Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by AbbVie Inc, H1 2017
  • Pipeline by Anacor Pharmaceuticals Inc, H1 2017
  • Pipeline by Apexigen Inc, H1 2017
  • Pipeline by Cell Medica Ltd, H1 2017
  • Pipeline by Exicure Inc, H1 2017
  • Pipeline by Immune Response BioPharma Inc, H1 2017
  • Pipeline by Novartis AG, H1 2017
  • Pipeline by Omnitura Therapeutics Inc, H1 2017
  • Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Pipeline by Optimum Therapeutics LLC, H1 2017
  • Pipeline by Orphit SAS, H1 2017
  • Pipeline by Peptinov SAS, H1 2017
  • Pipeline by R Pharm, H1 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Pipeline by Swedish Orphan Biovitrum AB, H1 2017
  • Pipeline by TWi Biotechnology Inc, H1 2017
  • Pipeline by XBiotech Inc, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Dormant Products, H1 2017 (Contd..2), H1 2017
  • Dormant Products, H1 2017 (Contd..3), H1 2017
  • Dormant Products, H1 2017 (Contd..4), H1 2017
  • Discontinued Products, H1 2017
  • Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top